DK2396660T3 - Forudsigelse af reaktion på platinbaseret terapi - Google Patents

Forudsigelse af reaktion på platinbaseret terapi

Info

Publication number
DK2396660T3
DK2396660T3 DK10704928.0T DK10704928T DK2396660T3 DK 2396660 T3 DK2396660 T3 DK 2396660T3 DK 10704928 T DK10704928 T DK 10704928T DK 2396660 T3 DK2396660 T3 DK 2396660T3
Authority
DK
Denmark
Prior art keywords
platinum
based therapy
predicting response
predicting
response
Prior art date
Application number
DK10704928.0T
Other languages
English (en)
Inventor
Karin Jirstroem
Jakob Eberhard
Original Assignee
Atlas Antibodies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/SE2009/000091 external-priority patent/WO2009102261A1/en
Priority claimed from EP09158084A external-priority patent/EP2241889A1/en
Priority claimed from EP09167847A external-priority patent/EP2293070A1/en
Application filed by Atlas Antibodies Ab filed Critical Atlas Antibodies Ab
Application granted granted Critical
Publication of DK2396660T3 publication Critical patent/DK2396660T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK10704928.0T 2009-02-16 2010-02-16 Forudsigelse af reaktion på platinbaseret terapi DK2396660T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/SE2009/000091 WO2009102261A1 (en) 2008-02-15 2009-02-16 Rbm3 as a marker for breast cancer prognosis
US16996309P 2009-04-16 2009-04-16
EP09158084A EP2241889A1 (en) 2009-04-16 2009-04-16 RBM3 protein in colorectal cancer prognostics
US23376909P 2009-08-13 2009-08-13
EP09167847A EP2293070A1 (en) 2009-08-13 2009-08-13 Means and methods for ovarian cancer prognosis
PCT/EP2009/067419 WO2010091763A1 (en) 2009-02-16 2009-12-17 Rbm3 as a marker for malignant melanoma prognosis
PCT/EP2010/051941 WO2010092190A2 (en) 2009-02-16 2010-02-16 Prediction of response to platinum-based therapy

Publications (1)

Publication Number Publication Date
DK2396660T3 true DK2396660T3 (da) 2013-10-28

Family

ID=41718882

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10704927.2T DK2396659T3 (da) 2009-02-16 2010-02-16 RBM3-protein i testikelkræftdiagnostik og -prognostik
DK10704928.0T DK2396660T3 (da) 2009-02-16 2010-02-16 Forudsigelse af reaktion på platinbaseret terapi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10704927.2T DK2396659T3 (da) 2009-02-16 2010-02-16 RBM3-protein i testikelkræftdiagnostik og -prognostik

Country Status (8)

Country Link
US (3) US8632984B2 (da)
EP (4) EP2396657B1 (da)
JP (3) JP5767116B2 (da)
CN (1) CN102334032B (da)
AU (4) AU2009339802B2 (da)
CA (3) CA2749392A1 (da)
DK (2) DK2396659T3 (da)
WO (5) WO2010091763A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091763A1 (en) * 2009-02-16 2010-08-19 Atlas Antibodies Ab Rbm3 as a marker for malignant melanoma prognosis
EP2524928A1 (en) 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer
AU2011316844A1 (en) * 2010-10-22 2013-06-06 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
US20120288480A1 (en) * 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
EP2573566A1 (en) 2011-09-20 2013-03-27 Atlas Antibodies AB RBM3 in prostate cancer prognostics
CN102590185B (zh) * 2012-01-11 2013-12-25 东南大学 以适体为识别单元的胶体晶体凝胶非标记可视化检测方法
WO2016004387A1 (en) * 2014-07-02 2016-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene expression signature for cancer prognosis
EP3023791A1 (en) 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
CN106611094B (zh) * 2015-10-15 2021-08-06 北京寻因生物科技有限公司 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统
CN113373151B (zh) * 2021-06-30 2022-05-03 华中科技大学同济医学院附属协和医院 环状RNAhsa_circ_0008399的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
WO2006071896A2 (en) * 2004-12-23 2006-07-06 The Hong Kong University Of Science And Technology Epitope-based sars vaccine
WO2007027906A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008051260A1 (en) 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
EP1862803A1 (en) * 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
EP2090890A1 (en) * 2008-02-15 2009-08-19 Atlas Antibodies AB RBM3 as a marker for breast cancer prognosis
US7902166B2 (en) 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
WO2010091763A1 (en) * 2009-02-16 2010-08-19 Atlas Antibodies Ab Rbm3 as a marker for malignant melanoma prognosis
EP2524928A1 (en) * 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer

Also Published As

Publication number Publication date
JP2012518163A (ja) 2012-08-09
US8632984B2 (en) 2014-01-21
US20120034317A1 (en) 2012-02-09
CA2749350A1 (en) 2010-08-19
JP2012518162A (ja) 2012-08-09
AU2009339802A1 (en) 2011-07-28
AU2010212769A1 (en) 2011-07-28
WO2010092190A2 (en) 2010-08-19
CA2749349A1 (en) 2010-08-19
EP2396659B1 (en) 2012-11-21
WO2010091763A1 (en) 2010-08-19
EP2396659A1 (en) 2011-12-21
JP5767116B2 (ja) 2015-08-19
AU2010212769B2 (en) 2014-07-17
CA2749392A1 (en) 2010-08-19
CN102334032A (zh) 2012-01-25
EP2396657A1 (en) 2011-12-21
EP2396346A1 (en) 2011-12-21
EP2396346B1 (en) 2013-04-03
AU2010212772B2 (en) 2014-07-17
EP2396660B1 (en) 2013-07-24
CN102334032B (zh) 2015-01-28
EP2396657B1 (en) 2013-11-13
AU2010212769C1 (en) 2014-10-09
JP5669757B2 (ja) 2015-02-18
WO2010092182A1 (en) 2010-08-19
HK1166371A1 (en) 2012-10-26
DK2396659T3 (da) 2013-03-04
EP2396660A2 (en) 2011-12-21
AU2009339802B2 (en) 2014-07-24
WO2010092190A3 (en) 2010-11-04
AU2010212764A1 (en) 2011-07-28
JP5611986B2 (ja) 2014-10-22
AU2010212764B2 (en) 2014-07-17
JP2012518164A (ja) 2012-08-09
WO2010092187A1 (en) 2010-08-19
US8747910B2 (en) 2014-06-10
WO2010092184A1 (en) 2010-08-19
AU2010212772A1 (en) 2011-07-28
US20120058202A1 (en) 2012-03-08
US20120269764A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
BRPI1010035A2 (pt) Células deficientes em fucosilação
PL2614063T3 (pl) Podstawione imidazopirydazyny
BRPI1008774A2 (pt) espiroamida substituída
EP2568873A4 (en) VACUUM RETRACTOR
EP2660110A4 (en) Wiper blade
DE112011103058A5 (de) Trepanieroptik
DE112011102080A5 (de) Kupplungszentralausrücker
DK2442899T3 (da) Rotorskive
EP2508411A4 (en) STRUCTURE
DE112011101333A5 (de) Parkouraufbau
DE102011002623A8 (de) Ventilsteuerzeitversteller
EP2441726A4 (en) LIFT
EP2571003A4 (en) RISK CALCULATION APPARATUS
EP2560655A4 (en) SUBSTITUTED PYRIMIDINES
FR2964098B1 (fr) Vitroceramique transparente
FI20090218A0 (fi) Bassokaiuttimen rakenne
EP2583770A4 (en) STRUCTURE ELEMENT
EP2448583A4 (en) Substituted 4-hydroxypyrimidine-5-carboxamides
BR112013000369A2 (pt) elemanto estrutural refratário
FR2964378B1 (fr) Vitroceramique transparente
EP2448584A4 (en) Substituted 4-hydroxypropyl-5-carboxamide
FI20096190A0 (fi) Tutkimuslaite
BR112013014731A2 (pt) tamavidina modificada
ES1073816Y (es) Termometro
BRPI0924006A2 (pt) estrutura